Mounjaro NHS weight loss criteria: who qualifies and what are your options?

Where the NHS criteria sit right now — and why 'qualifying' is only part of the picture

NICE published its recommendation for tirzepatide in December 2024 and NHS England began implementation from June 2025. The first cohort is deliberately narrow: adults with a BMI of 40 or above who also have four or more of the five qualifying comorbidities, high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. A second cohort opened in June 2026, covering BMIs of 35 to 39.9 with the same four-condition requirement. A third phase, targeting BMI 40-plus with at least three conditions, is expected around March 2027.

That progression matters because many people reading this page will fall just outside the current threshold, perhaps with a BMI of 38 and three comorbidities, or a BMI of 42 but only two. For anyone in that position, the NHS route is not yet open. You can read a detailed breakdown of the current NHS Mounjaro criteria on our dedicated criteria page.

Even within the qualifying cohorts, access is not automatic. GP practices may prescribe under the new 2026/27 contract, but participation is optional, so provision varies considerably by area, and if you are in Scotland you can find out more about how Mounjaro is being rolled out through NHS Fife as one example of how local implementation differs. Every patient must also engage with 'wrap-around' diet and activity support as part of NHS treatment. Meeting the numbers on paper is the start of the process, not the end.

What the rollout timetable means if you are deciding whether to wait or go private

This is the real decision for most people who land on this page. If you currently have a BMI above 40 and four qualifying conditions, the NHS route exists in principle and your GP surgery is the first call. If you sit in the 35–39.9 bracket with four conditions, Cohort 2 is now open, though waiting lists at specialist services can stretch for months, and not every ICB has activated GP prescribing yet.

For everyone else, the practical choice is to wait for a future cohort or seek private treatment now. If you are still weighing up whether you can get Mounjaro on the NHS for weight loss given your current BMI and conditions, it is worth checking the eligibility detail before assuming the answer is no. Private prescribing through a GPhC-registered pharmacy does not require a referral or a waiting list; it requires a clinical assessment that confirms you meet the licensed criteria for the medicine. The licensed eligibility threshold is notably lower than the NHS one: adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition, may be assessed. A prescriber still reviews each case individually.

Cost is part of this decision too. Eli Lilly increased UK list prices significantly from September 2025, and private monthly costs now typically range from around £149 to £375 depending on dose and provider. Our page on the Lilly price increase covers the background in full. It is worth sitting with the numbers before committing either way.

How private assessment works if the NHS route is not open to you yet

A private consultation for Mounjaro through a regulated pharmacy is a clinical process, not a formality. At nume, a GPhC-registered Independent Prescriber reads every submission personally (not software, not a scoring algorithm) on the same day it arrives. That includes verifying your identity with photo ID and confirming your current weight on a short video call, so the prescriber is making decisions based on real information rather than self-reported figures.

If you are already on Mounjaro elsewhere and want to transfer, or if you are at a dose that needs increasing, evidence of your current treatment is reviewed before anything moves forward. Our clinical team's approach is described in more detail on the clinical team page.

Orders placed before noon on a working day are dispatched the same day once approved, arriving by tracked DPD delivery the next working day, which for many people means the pen arrives before the school run is even a thought. Packaging is plain and unbranded. There are no subscriptions and no auto-renewals; every repeat order goes through a fresh clinical review, and our page on NHS Mounjaro weight loss explains how the NHS programme approaches ongoing monitoring if you want to compare the two. You can explore what treatment involves on the weight-loss overview page.

For a broader look at all available options, the free consultation page is the starting point. A prescriber can assess whether Mounjaro is clinically suitable for you and, if so, at what dose treatment would begin, and you can also read about how the weight loss jab is being made available through the NHS to understand where the programme currently stands. There is no obligation from a consultation alone.